University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

1,2-Dichloroethane (CAS 107-06-2)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
mgl per sto sub vsc mgl sub lun vsc liv lun mgl ute 14.6m,v 138m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   liv = liver. lun = lung. mgl = mammary gland. per = peritoneal cavity. sto = stomach. sub = subcutaneous tissue. ute = uterus. vsc = vascular system. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50. v = Variation is greater than ten-fold among statistically significant (two-tailed p<0.1) TD50 values from different positive experiments.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

1,2-Dichloroethane: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

1,2-DICHLOROETHANE (ethylene dichloride, EDC) 107-06-2 2002 M f b6c gav 78w90 TR55 : 0 92.5mg 183.mg MXB MXB v 61.2mg / P<.0005 38.2mg 113.mg 1/20 16/50 19/50 lun:a/a; mgl:acn. C lun a/a v 118.mg / P<.0005 c 65.2mg 280.mg 1/20 7/50 15/50 mgl acn v 133.mg / P<.0005 c 71.4mg 312.mg 0/20 9/50 7/50 TBA MXB v 36.0mg / P<.0005 23.5mg 65.4mg 6/20 33/50 29/50 liv MXB v 4.74gm / P<.8 349.mg n.s.s. 1/20 0/50 1/50 liv:hpa,hpc,nnd. lun MXB v 112.mg / P<.0005 63.2mg 253.mg 1/20 7/50 16/50 lun:a/a,a/c. 2003 M f b6c gav 78w90 TR55 : pool 0 92.5mg 183.mg lun a/a v 116.mg / P<.0005 c 64.5mg 244.mg 2/60 7/50 15/50 mgl acn v 133.mg / P<.0005 c 71.4mg 280.mg 0/60 9/50 7/50 ute MXA v 230.mg / P<.0005 c 108.mg 598.mg 0/60 5/50 5/50 ute:esp,ess. sto sqc v 438.mg / P<.003 170.mg 3.27gm 1/60 2/50 5/50 S 2004 M m b6c gav 78w90 TR55 : 0 60.0mg 120.mg lun a/a v 89.7mg * P<.0005 c 49.7mg 230.mg 0/20 1/50 15/50 liv hpc v 133.mg * P<.04 62.1mg n.s.s. 1/20 6/50 12/50 S TBA MXB v 57.7mg * P<.02 29.3mg n.s.s. 4/20 15/50 28/50 liv MXB v 133.mg * P<.04 62.1mg n.s.s. 1/20 6/50 12/50 liv:hpa,hpc,nnd. lun MXB v 89.7mg * P<.0005 49.7mg 230.mg 0/20 1/50 15/50 lun:a/a,a/c. 2005 M m b6c gav 78w90 TR55 : pool 0 60.0mg 120.mg lun a/a v 89.7mg * P<.0005 c 49.7mg 186.mg 0/60 1/50 15/50 liv hpc v 148.mg * P<.02 67.0mg n.s.s. 4/60 6/50 12/50 S 2006 M f bdj inh 24m24 2378 0 12.7mg 38.0mg 114.mg Nagano;apor,741-746;1998/pers.comm. lun mix e 510.mg * P<.02 + 219.mg n.s.s. 5/49 1/50 4/50 11/50 lun a/a e 766.mg * P<.05 + 281.mg n.s.s. 4/49 1/50 3/50 8/50 liv hpa e 849.mg * P<.02 + 330.mg n.s.s. 1/49 1/50 1/50 6/50 mgl adc e 864.mg * P<.03 + 319.mg n.s.s. 1/49 2/50 1/50 6/50 liv mix e 912.mg * P<.05 + 326.mg n.s.s. 2/49 1/50 2/50 6/50 ute esp e 983.mg * P<.03 + 361.mg n.s.s. 2/49 0/50 1/50 6/50 lun a/c e 1.83gm * P<.2 + 511.mg n.s.s. 1/49 0/50 1/50 3/50 liv hpc e no dre P=1. 1.22gm n.s.s. 1/49 0/50 1/50 0/50 2007 M m bdj inh 24m24 2378 0 10.6mg 31.7mg 95.0mg liv hes e 576.mg * P<.2 + 183.mg n.s.s. 0/50 4/49 6/50 5/50 lun a/c e 631.mg * P<.3 160.mg n.s.s. 4/50 10/49 12/50 10/50 liv hpa e no dre P=1. 528.mg n.s.s. 14/50 9/49 6/50 6/50 liv hpc e no dre P=1. 348.mg n.s.s. 17/50 8/49 15/50 9/50 2008 M f swi inh 18m25 1001m 0 5.31mg 11.9mg 53.1mg 195.mg Maltoni;banb,5,3-33;1980 liv mix ev 16.9gm * P<.7 - 2.76gm n.s.s. 0/133 0/89 0/88 1/87 0/84 lun ade ev 55.4gm * P<1. - 1.80gm n.s.s. 4/133 4/89 2/88 2/87 3/84 liv hpt ev no dre P=1. - 67.7mg n.s.s. 0/133 0/89 0/88 0/87 0/84 liv ang ev no dre P=1. - 67.7mg n.s.s. 0/133 0/89 0/88 0/87 0/84 tba mix ev no dre P=1. - 1.52gm n.s.s. 27/133 19/89 17/88 15/87 11/84 2009 M m swi inh 18m25 1001m 0 4.43mg 9.19mg 49.7mg 156.mg liv ang ev no dre P=1. - 47.1mg n.s.s. 0/111 0/69 0/89 0/87 0/81 liv hpt ev no dre P=1. - 47.1mg n.s.s. 4/111 0/69 0/89 0/87 0/81 liv mix ev no dre P=1. - 47.1mg n.s.s. 1/111 0/69 0/89 0/87 0/81 lun ade ev no dre P=1. - 2.69gm n.s.s. 4/111 1/69 4/89 3/87 0/81 tba mix ev no dre P=1. - 285.mg n.s.s. 14/111 4/69 12/89 9/87 (2/81) 2010 R f osm gav 18m26 TR55 : 0 24.0mg 48.0mg mgl MXA dsv 5.49mg / P<.0005 c 1.98mg 13.7mg 0/20 15/50 24/50 mgl:acn,fba. mgl fba dsv 5.84mg / P<.0005 2.02mg 17.2mg 0/20 14/50 8/50 S mgl acn dsv 74.8mg / P<.0005 c 40.8mg 147.mg 0/20 1/50 18/50 TBA MXB dsv 3.19mg / P<.0005 1.47mg 7.60mg 7/20 24/50 33/50 liv MXB dsv 60.6mg * P<.2 10.4mg n.s.s. 0/20 2/50 0/50 liv:hpa,hpc,nnd. 2011 R f osm gav 18m26 TR55 : pool 0 24.0mg 48.0mg mgl MXA dsv 5.63mg / P<.0005 c 2.27mg 13.8mg 6/60 15/50 24/50 mgl:acn,fba. mgl fba dsv 6.38mg / P<.0005 2.42mg 18.9mg 5/60 14/50 8/50 S --- hes dsv 19.5mg * P<.0005 4.35mg 99.1mg 0/60 4/50 4/50 S mgl acn dsv 54.0mg / P<.0005 c 20.3mg 125.mg 1/60 1/50 18/50 2012 R m osm gav 18m26 TR55 : 0 24.0mg 48.0mg MXB MXB dsv 11.5mg / P<.0005 3.91mg 27.3mg 0/20 12/50 14/50 ---:hes; sto:sqc. C --- hes dsv 15.0mg * P<.0005 c 4.16mg 56.2mg 0/20 9/50 7/50 sto sqc dsv 46.3mg / P<.0005 c 17.4mg 153.mg 0/20 3/50 9/50 TBA MXB dsv 3.18mg / P<.0005 1.12mg 10.7mg 4/20 20/50 20/50 liv MXB dsv 132.mg / P<.07 23.8mg n.s.s. 0/20 0/50 2/50 liv:hpa,hpc,nnd. 2013 R m osm gav 18m26 TR55 : pool 0 24.0mg 48.0mg --- hes dsv 18.4mg * P<.0005 c 4.98mg 61.0mg 1/60 9/50 7/50 sub fib dsv 43.2mg / P<.0005 c 17.6mg 108.mg 0/60 5/50 6/50 sto sqc dsv 46.3mg / P<.0005 c 17.4mg 121.mg 0/60 3/50 9/50 2014 R f cdr inh 24m24 1962 0 17.5mg Cheever;faat,14,243-261;1990 liv hpc e 594.mg P<.3 - 96.7mg n.s.s. 0/50 1/50 liv nnd e no dre P=1. - 110.mg n.s.s. 1/50 1/50 tba tum e no dre P=1. - 5.32mg n.s.s. 47/50 47/50 2015 R m cdr inh 24m24 1962 0 12.3mg liv nnd e 206.mg P<.1 - 50.6mg n.s.s. 0/50 2/50 liv hpc e no dre P=1. - 76.8mg n.s.s. 1/50 1/50 tba tum e 17.9mg P<.4 - 4.15mg n.s.s. 42/50 45/50 2016 R f f3d inh 24m24 2378 0 3.01mg 12.1mg 48.2mg Nagano;apor,741-746;1998/pers.comm. mgl mix e 64.5mg * P<.0005 + 35.8mg 176.mg 8/50 8/50 11/50 25/50 mgl fba e 136.mg * P<.002 + 66.8mg 593.mg 4/50 1/50 6/50 13/50 sub fib e 347.mg * P<.002 + 141.mg 1.59gm 0/50 0/50 1/50 5/50 mgl ade e 191.mg * P<.02 + 78.5mg n.s.s. 3/50 5/50 5/50 11/50 mgl adc e 489.mg * P<.06 + 155.mg n.s.s. 1/50 2/50 0/50 5/50 liv tum e no dre P=1. 23.7mg n.s.s. 0/50 0/50 0/50 0/50 2017 R m f3d inh 24m24 2378 0 2.11mg 8.44mg 33.8mg mgl mix e 203.mg * P<.01 + 80.2mg 15.1gm 1/50 2/50 1/50 7/50 mgl fba e 243.mg * P<.002 + 99.0mg 1.12gm 0/50 0/50 1/50 5/50 sub fib e 108.mg * P<.04 + 42.3mg n.s.s. 6/50 9/50 12/50 15/50 thy cca e 199.mg * P<.09 65.7mg n.s.s. 2/50 5/50 6/50 8/50 per mso e 291.mg * P<.03 + 101.mg n.s.s. 1/50 1/50 1/50 5/50 liv hpa e 3.35gm * P<.9 158.mg n.s.s. 2/50 1/50 3/50 2/50 2018 R f sda inh 18m31 1001m 0 1.08mg 2.15mg 10.4mg 39.8mg Maltoni;banb,5,3-33;1980 liv mix ev no dre P=1. - 19.7mg n.s.s. 0/90 0/90 0/90 0/90 0/90 mam mix ev no dre P=1. - 117.mg n.s.s. 52/90 65/90 43/90 58/90 52/90 tba mix ev no dre P=1. - 111.mg n.s.s. 56/90 65/90 43/90 56/90 54/90 2019 R f sda inh 18m31 1001n 0 1.08mg 2.15mg 10.4mg 39.8mg mam mix ev 38.1mg Z P<.07 - 14.6mg n.s.s. 38/90 65/90 43/90 58/90 (52/90) liv mix ev no dre P=1. - 19.7mg n.s.s. 0/90 0/90 0/90 0/90 0/90 tba mix ev 48.8mg Z P<.2 - 16.4mg n.s.s. 38/90 65/90 43/90 56/90 (54/90) 2020 R m sda inh 18m33 1001m 0 .670mg 1.79mg 7.09mg 26.8mg liv mix ev no dre P=1. - 15.9mg n.s.s. 0/90 0/90 0/89 0/90 0/89 tba mix ev 2.40gm Z P<1. - 45.6mg n.s.s. 14/90 30/90 13/89 20/90 (15/89) 2021 R m sda inh 18m33 1001n 0 .670mg 1.79mg 7.09mg 26.8mg liv mix ev no dre P=1. - 15.9mg n.s.s. 0/90 0/90 0/89 0/90 0/89 tba mix ev no dre P=1. - 51.5mg n.s.s. 17/90 30/90 13/89 20/90 (15/89)

Mutagenicity in Salmonella: positive
SMILES Code for 1,2-Dichloroethane: ClCCCl
InChI Code for 1,2-Dichloroethane: InChI=1/C2H4Cl2/c3-1-2-4/h1-2H2
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for 1,2-Dichloroethane: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10